Mabion SA (MAB) – Financial and Strategic SWOT Analysis Review

Mabion SA (MAB) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
35
Pharmaceuticals and Healthcare
Poland

Mabion SA (MAB) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mabion SA (Mabion) is a Poland-based biotechnology company. It carries out research and development (R&D) in the area of medicine and pharmacy. The company is involved in developing latest generation of drugs which are based on humanized monoclonal antibodies. The company’s development process involves the humanization of monoclonal antibodies that enables the production of targeted drugs that offer better effectiveness and lower toxicity of the therapy. Mabion is headquartered at Kutno, Lodz province, Poland.

The company’s strategy is to be associated with strong local marketing and distribution partners. In line with this strategy, in April 2014, the company signed an agreement with LYFIS ehf. Iceland regarding the registration, distribution and sale of the drug MabionCD20 in Iceland.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Mabion SA – Key Facts 6
Mabion SA – Key Employees 7
Mabion SA – Major Products and Services 8
Mabion SA – Pharmaceutical Pipeline Products Data 9
Mabion SA, Pipeline Products by Therapy Area 9
Mabion SA, Pipeline Products by Development Phase 10
Mabion SA – History 12
Mabion SA – Company Statement 14
Mabion SA – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Mabion SA – Business Description 16
Mabion SA – Corporate Strategy 17
Mabion SA – SWOT Analysis 18
SWOT Analysis – Overview 18
Mabion SA – Strengths 18
Strength – Comprehensive Range of Services 18
Strength – Strong Foundation 18
Mabion SA – Weaknesses 19
Weakness – Declining Profitability 19
Mabion SA – Opportunities 20
Opportunity – Contracts and Agreements 20
Opportunity – Pipeline Products 20
Opportunity – Rapidly Growing Biosimilars Market 20
Mabion SA – Threats 21
Threat – Intense Competition 21
Threat – Stringent Government Regulations 21
Threat – Uncertain R&D Outcomes 21
Mabion SA – Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios – Capital Market Ratios 23
Financial Ratios – Annual Ratios 24
Performance Chart 25
Financial Performance 25
Financial Ratios – Interim Ratios 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Mabion SA, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 28
Mabion SA, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 29
Mabion SA, Recent Deals Summary 30
Section 5 – Appendix 31
Methodology 31
Ratio Definitions 31
About GlobalData 35
Contact Us 35
Disclaimer 35



List of Tables
Mabion SA, Key Facts 6
Mabion SA, Key Employees 7
Mabion SA, Major Products and Services 8
Mabion SA, Number of Pipeline Products by Therapy Area 9
Mabion SA, Number of Pipeline Products by Development Stage 10
Mabion SA, Pipeline Products By Therapy Area and Development Phase 11
Mabion SA, History 12
Mabion SA, Other Locations 15
Mabion SA, Key Competitors 22
Mabion SA, Ratios based on current share price 23
Mabion SA, Annual Ratios 24
Mabion SA, Interim Ratios 26
Mabion SA, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 28
Mabion SA, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 29
Mabion SA, Recent Deals Summary 30
Currency Codes 31
Capital Market Ratios 31
Equity Ratios 32
Profitability Ratios 32
Cost Ratios 33
Liquidity Ratios 33
Leverage Ratios 34
Efficiency Ratios 34



List of Figures
Mabion SA, Pipeline Products by Therapy Area 9
Mabion SA, Pipeline Products by Development Phase 10
Mabion SA, Performance Chart (2009 – 2013) 25
Mabion SA, Ratio Charts 27
Mabion SA, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 28
Mabion SA, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 29

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.